Is this your company? Get featured or correct your listing →
Recent changes
- Oct 20, 2026Oct 20, 2026Lycia Therapeutics Targets $937.7M In US IPO Pulse story
- Jun 10, 2026Jun 10, 2026Raised $75M SEC EDGAR Form D
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2026 | funding round | $75M | — | SEC EDGAR Form D |
Latest Pulse
- Oct 21, 20262026's IPO Window Rewards Proof, Not PromisePublic investors aren't closing the IPO window in 2026 -- they're being unsparing toward growth stories without current profitability, pricing modest biotech and SPAC deals while mega-valuation infrastructure names keep stalling.→
- Oct 20, 2026Lycia Therapeutics Targets $937.7M In US IPOLycia Therapeutics set terms for its Nasdaq IPO, offering 14.7 million shares at $16-$18 to raise up to $264.6 million at a valuation of up to $937.7 million, as the Nobel laureate-founded biotech joins 2026's busy IPO window.→
Coverage Timeline
newest firstAll Coverage
Value Add Research
Related Companies
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.